Tiger Brokers

SKB BIO Shares Surge Over 5% on Positive Phase III Results for TROP2 ADC Developed with Merck

Stock News
May 21

SKB BIO (06990) rose more than 5%. As of press time, the stock was up 3.3%, trading at HK$451.4 with a turnover of HK$166 million. Recently, according to an announcement from SKB BIO, Merck announced that the investigational TROP2-targeted antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), co-developed with the company, met the primary endpoints of overall survival (OS) and progression-free survival (PFS) in the pivotal global Phase III TroFuse-005 trial for certain patients with advanced or recurrent endometrial cancer. TroFuse-005 is the first global Phase III trial for this patient population to demonstrate statistically significant improvements in both OS and PFS compared to chemotherapy. It is also the first and only ADC drug to achieve this breakthrough in this type of endometrial cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10